A method for preparing a thiourea-based macrocyclic peptide, the product and its application.
The preparation method of thiourea-based macrocyclic peptides solves the problems of low stability and low transmembrane efficiency of peptide drugs, and realizes cyclization modification of peptides under mild conditions, which is suitable for peptide drug development and anti-tumor research.
Patent Information
- Application Number
- CN202510294340.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-13
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-03-13
AI Technical Summary
Existing peptide drugs are easily digested by enzymes, resulting in poor metabolic stability, short half-life, and low transmembrane efficiency and oral bioavailability, which limits the development of peptide drugs.
A method for preparing thiourea-based macrocyclic peptides was adopted, which involved mixing a polypeptide, a base, and N,N'-thiocarbonyl diimidazole with a reaction solvent, followed by the slow addition of a diamine compound. After the reaction was completed, the mixture was freeze-dried and purified to obtain the thiourea-based macrocyclic peptide.
Cyclic modification of peptides was achieved under mild conditions, which improved the stability and activity of peptides. It has wide applicability and is suitable for cyclization modification and anti-tumor research of a variety of natural peptides.
Smart Images

Figure CN120098066B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of organic synthesis technology, and in particular to a method for preparing a thiourea-based macrocyclic peptide, the product thereof, and its application. Background Technology
[0002] In recent years, with the increasing maturity of biotechnology and peptide synthesis technology, peptide drugs have attracted widespread attention from drug developers both domestically and internationally. Peptides, as a special biomolecule situated between large proteins and amino acids, possess many unique characteristics and advantages. Peptide drugs combine the specific cell selectivity of large protein drugs with the low-cost characteristics of small molecule drugs. Due to their high biological activity, broad indications, small dosage, low toxicity, and significant efficacy, they have become an important direction for new drug development both domestically and internationally. Currently, they are widely used in the prevention, diagnosis, and treatment of diseases such as cancer, hepatitis, diabetes, and AIDS, and have broad development prospects. However, some existing peptide drugs are easily enzymatically hydrolyzed, leading to poor metabolic stability, short half-life, and low transmembrane efficiency and oral bioavailability, which seriously restricts the development of peptide drugs.
[0003] Cyclic peptides are closed-loop peptide chains composed of multiple amino acids linked by peptide bonds. They have important applications in biochemistry and medicinal chemistry. Due to their unique cyclic structure, cyclic peptides exhibit different biological activities and stability compared to ordinary linear peptides. This stability primarily stems from their cyclic structure, making them less susceptible to enzymatic degradation in vivo, thus prolonging their biological activity. Furthermore, their smaller molecular weight and good cell membrane permeability allow them to easily cross cell membranes, enter the cell, and interact with intracellular targets to achieve their biological functions. Therefore, cyclic peptides hold significant potential in drug development, enabling the creation of novel drugs with high efficacy, low toxicity, and high bioavailability. In summary, peptide chain cyclization makes cyclic peptides fundamentally different from linear peptides. Cyclization not only improves the structural properties of the peptide chain but also enhances pharmacokinetic properties, such as absorption and biomembrane permeability, essential for achieving protein targets. The constrained structure of peptides lowers their energy barrier, allowing them to adapt to the membrane environment and bind to transport proteins, thereby increasing passive diffusion and active transport. By introducing non-peptide and non-amino acid elements, cyclic peptides can also further improve their pharmacokinetic and pharmacodynamic properties.
[0004] Cyclic modification of peptides not only significantly enhances their stability and activity but also greatly enriches their diversity, making it a key strategy in peptide research. In recent years, chemists both domestically and internationally have made significant progress in peptide macrocyclization strategies. Chemical cyclization methods have become increasingly mature and are attracting growing attention from chemists. For example, naïve cyclization requires no protecting groups, pre-modification, or organic solvents, exhibits strong compatibility, and can achieve efficient cyclization of peptides from 5 to 20 amino acid residues (J. Am. Chem. Soc., 2023, 145, 27218–27224.); the C-H bond activation strategy selectively activates alkyl C-H bonds on chain peptide substrates through metal catalysis, and then couples them intramolecularly with iodine-substituted aromatic amino acid side chains to generate cyclic products (Acc. Chem.). Res. 2012, 45, 788–802.; Nat. Commun., 2023, 14, 39703.); Click chemistry cyclization, utilizing efficient click reactions between specific chemical groups to achieve cyclization (Nat. Commun., 2024, 15, 7308.; Org. Lett., 2024, 26, 2601–2605.); Enzymatic cyclization, utilizing specific enzymes to catalyze intramolecular cyclization reactions of peptides (Organic Letters, 2024, 26, 2601–2605.); N-terminal modification and cyclization, achieving main-chain-side-chain cyclization of peptides through N-terminal chemical modifications (such as thiol modification) (Angew. Chem. Int. Ed., 2020, 59, 14246–14250.).
[0005] However, existing peptide cyclization methods often have limitations and shortcomings, such as harsh reaction conditions, complex operations, and high costs. These problems greatly restrict the widespread application of peptide cyclization technology. Traditional amide cyclization strategies require the formation of specific cyclization conformations, which is an entropy-unfavorable process, making cyclization relatively difficult (Chem. Rev., 2015, 115, 8769–8834). Therefore, there is an urgent need to develop a more suitable peptide cyclization method to overcome the harsh reaction conditions and improve the efficiency of cyclization. Summary of the Invention
[0006] Based on the above, this invention provides a method for preparing a thiourea-based macrocyclic peptide, a product thereof, and its application.
[0007] To achieve the above objectives, the present invention provides the following solution:
[0008] One of the technical solutions of this invention is a method for preparing a thiourea-based macrocyclic peptide, comprising the following steps:
[0009] The polypeptide, base, and N,N'-thiocarbonyl diimidazole were mixed with the reaction solvent and stirred for reaction. After the reaction was complete, a certain amount of solvent (N,N-dimethylformamide) was diluted with the diamine compound and slowly added dropwise to the above reaction system. After the reaction was completed, the reaction solution was freeze-dried, separated and purified to obtain the thiourea macrocyclic peptide.
[0010] The polypeptide is a linear polypeptide containing at least two -NH2 groups.
[0011] In a preferred embodiment of the present invention, the polypeptide is a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, etc.
[0012] In a preferred embodiment of the present invention, the polypeptide contains two alkylamines.
[0013] In a preferred embodiment of the present invention, the polypeptide contains amino acid residues such as lysine, alanine, tryptophan, arginine, phenylalanine, tyrosine, valine, leucine, or isoleucine.
[0014] In a preferred embodiment of the present invention, the polypeptide is an oligopeptide containing lysine, an active peptide containing lysine, or a polypeptide drug containing lysine.
[0015] In a preferred embodiment of the present invention, the polypeptide is a polypeptide with exposed amino, thiol, imidazole, guanidine, phenolic hydroxyl, or amide groups on its side chains.
[0016] In a preferred embodiment of the present invention, the structure of the polypeptide is shown in Formula A:
[0017]
[0018] In formula A, R1 and R2 are independently methyl, ethyl, acetyl, tert-butoxycarbonyl, benoxycarbonyl, 9-fluorenylmethoxycarbonyl, carboxyl, or amino.
[0019] In a preferred embodiment of the present invention, the molar ratio of the polypeptide to the N,N'-thiocarbonyldiimidazole is 1:(1-5).
[0020] In a preferred embodiment of the present invention, the molar ratio of the polypeptide to the diamine compound is 1:2.
[0021] In a preferred embodiment of the present invention, the base is triethylamine, and the molar ratio of the polypeptide to the base is 1:(1-10).
[0022] In a preferred embodiment of the present invention, the reaction solvent is one or two of acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, and tetrahydrofuran. When the reaction solvent is a mixture of two of the above solvents, the volume ratio of the two solvents is (0.2-5):1.
[0023] This invention does not impose any particular limitation on the amount of reaction solvent used. The amount of reaction solvent should be sufficient to fully dissolve the polypeptide and N,N'-thiocarbonyl diimidazole, etc., and to ensure that the reaction proceeds smoothly.
[0024] In a preferred embodiment of the present invention, the diamine compound has the structural formula H2N-R3-NH2; wherein R3 is trimethylene, 1,3-dimethylenebenzene, cyclohexane, a benzene ring, or a polyethylene glycol segment.
[0025] The reaction process is shown in the following reaction equation:
[0026]
[0027] In a preferred embodiment of the present invention, the reactions are all carried out at room temperature, in an air atmosphere, and under non-directly exposed conditions, and the reaction time is 12 to 24 hours.
[0028] Throughout the entire reaction process, this invention continuously monitors the reaction solution using mass spectrometry to ensure complete conversion of the raw material peptides.
[0029] The reaction process includes lyophilization, separation, and purification. Preparative HPLC is used for precise separation and purification. The purpose of lyophilization is to remove the solvent.
[0030] In the reaction formula, (2) refers to the slow addition of the diamine compound to the reaction system after dilution with an organic solvent. The amount of organic solvent used for dilution in this invention is not particularly limited, and commonly used dilution amounts in the art can be used, such as dilution to a concentration of 2 to 20 mmol / L for the diamine compound.
[0031] This invention does not impose special limitations on the freeze-drying parameter settings, such as pressure, temperature, and time; freeze-drying parameter settings commonly used by those skilled in the art can be adopted.
[0032] The polypeptide cyclization products (i.e., thiourea macrocyclic peptides) obtained through the above-mentioned thiourea-based polypeptide cyclization technique can be used to develop polypeptide drugs with specific functions and to study the structure and function of compounds. This method can be used for the cyclization modification of various natural polypeptides, as well as for the cyclization modification of various non-protective peptides, and can be used for anti-tumor and membrane permeability studies.
[0033] The second technical solution of the present invention is a thiourea macrocyclic peptide prepared according to the above preparation method.
[0034] The third technical solution of the present invention is the application of the above-mentioned thiourea macrocyclic peptide in the preparation of a drug for treating anti-tumor diseases, wherein the anti-tumor cells are Coca2 cells and / or TE-1 cells.
[0035] The present invention discloses the following technical effects:
[0036] (1) This invention belongs to the field of chemical synthesis. It can be easily reacted at room temperature without the need for high temperature, high pressure or other harsh reaction conditions.
[0037] (2) The present invention is convenient and simple to operate, has high substrate applicability, does not require a directing group, does not involve metals, and can be exposed to air for reaction without the need for inert gas protection.
[0038] (3) In terms of applicability, the present invention can cover the needs of macrocyclic modification from ten-membered rings to thirty-membered rings and above, thus effectively solving the current difficulties faced by macrocyclic modification.
[0039] (4) This invention is used for peptide diversity modification, which can provide a theoretical basis for the development of specific functional peptide drugs and the study of compound structure and function.
[0040] In summary, this invention, under mild conditions, utilizes a thiourea-based peptide cyclization technique to achieve peptide cyclization modification, laying a solid theoretical foundation for the development of specific functional peptides. This invention has significant implications for research in the fields of biomedicine and biotechnology. Attached Figure Description
[0041] Figure 1 This is an LC tracer image of the reaction solution before purification in Example 1;
[0042] Figure 2 This is an LC tracer image of the target product obtained after purification in Example 1;
[0043] Figure 3 This is an LC tracer image of the reaction solution before purification in Example 2;
[0044] Figure 4 This is an LC tracer image of the target product obtained after purification in Example 2;
[0045] Figure 5 This is an LC tracer image of the reaction solution before purification in Example 3;
[0046] Figure 6 This is an LC tracer image of the target product obtained after purification in Example 3;
[0047] Figure 7 This is an LC tracer image of the reaction solution before purification in Example 4;
[0048] Figure 8 This is an LC tracer image of the target product obtained after purification in Example 4;
[0049] Figure 9 This is an LC tracer image of the reaction solution before purification in Example 5;
[0050] Figure 10 This is an LC tracer image of the target product obtained after purification in Example 5;
[0051] Figure 11 This is an LC tracer image of the reaction solution before purification in Example 6;
[0052] Figure 12 This is an LC tracer image of the target product obtained after purification in Example 6;
[0053] Figure 13 This is an LC tracer image of the reaction solution before purification in Example 7;
[0054] Figure 14 This is an LC tracer image of the target product obtained after purification in Example 7;
[0055] Figure 15 This is an LC tracer image of the reaction solution before purification in Example 8;
[0056] Figure 16 This is an LC tracer image of the target product obtained after purification in Example 8;
[0057] Figure 17 This is an LC tracer image of the reaction solution before purification in Example 9;
[0058] Figure 18 This is an LC tracer image of the target product obtained after purification in Example 9;
[0059] Figure 19 This is an LC tracer image of the reaction solution before purification in Example 10;
[0060] Figure 20 This is an LC tracer image of the target product obtained after purification in Example 10;
[0061] Figure 21 This is an LC tracer image of the reaction solution before purification in Example 11;
[0062] Figure 22 This is an LC tracer image of the target product obtained after purification in Example 11;
[0063] Figure 23 This is an LC tracer image of the reaction solution before purification in Example 12;
[0064] Figure 24 This is an LC tracer image of the target product obtained after purification in Example 12;
[0065] Figure 25 This is an LC tracer image of the reaction solution before purification in Example 13;
[0066] Figure 26 This is an LC tracer image of the target product obtained after purification in Example 13;
[0067] Figure 27 This is an LC tracer image of the reaction solution before purification in Example 14.
[0068] Figure 28 This is an LC tracer image of the target product obtained after purification in Example 14;
[0069] Figure 29 This is an LC tracer image of the reaction solution before purification in Example 15;
[0070] Figure 30 This is an LC tracer image of the target product obtained after purification in Example 15.
[0071] Figure 31 Example 1 shows the effect of testing the anti-cancer cell activity.
[0072] Figure 32 Example 1: Anti-cancer cell activity IC 50 Result image.
[0073] Figure 33 Example 2 shows the effect of testing the anti-cancer cell activity.
[0074] Figure 34 Example 2: Anti-cancer cell activity IC 50 Result image. Detailed Implementation
[0075] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0076] To address the shortcomings and deficiencies of existing methods for preparing cyclic peptides, this invention provides a method for preparing thiourea-based macrocyclic peptides. This method involves a two-step reaction. First, a polypeptide containing at least two -NH2 groups is reacted with N,N'-thiocarbonyl diimidazole under the action of common bases and solvents to generate an isothiocyanate-treated polypeptide. Subsequently, a simple diamine (including but not limited to 1,3-propanediamine, m-cyclohexanediamine, and o-cyclohexanediamine) diluted with an appropriate solvent is introduced into the predetermined reaction system by slow dropwise addition to generate the target cyclized product. This reaction exhibits advantages such as mild reaction conditions, simple operation, and high reaction efficiency, and has good application prospects.
[0077] Unless otherwise specified, the technical solutions described in this invention are all conventional solutions in the field, and the reagents or raw materials used are all purchased from commercial channels or are publicly available unless otherwise specified.
[0078] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.
[0079] Example 1
[0080] 0.02 mmol of peptide A1 (Ac-Lys-Trp-Lys-OMe), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were added to a 25 mL glass tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature for 12 hours until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC to obtain the final 24-membered ring peptide product B1, which was then dried using a lyophilizer. A small amount of the unpurified residue and the purified sample were prepared into a 10 mM solution using acetonitrile and water for LC analysis. The LC yield was 37%.
[0081] The reaction formula and the structural characterization data of the resulting product are shown below:
[0082]
[0083] HRMS-ESI(m / z):calcd for [MH] - C 31 H 45 N8O5S2 - :673.2960; found:673.2964.
[0084] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 1 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 2 As shown.
[0085] Example 2
[0086] 0.02 mmol of peptide A1 (Ac-Lys-Trp-Lys-OMe), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-phenylenediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-phenylenediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, a 26-membered ring peptide, was obtained. The LC yield was 70%.
[0087] The reaction formula and the structural characterization data of the resulting product are shown below:
[0088]
[0089] HRMS-ESI(m / z):calcd for [M+H] + C 36 H 49 N8O5S2 + :737.3262; found:737.3253.
[0090] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 3 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 4 As shown.
[0091] Example 3
[0092] 0.02 mmol of peptide A2 (Ac-Lys-Leu-Ala-Phe-Lys-OMe), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were sequentially added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, a 30-membered ring peptide, was obtained. LC yield is 37%.
[0093] The reaction formula and the structural characterization data of the resulting product are shown below:
[0094]
[0095] HRMS-ESI(m / z):calcd for [MH] - C 38 H 60 N9O7S2 - :818.4063; found:818.4064.
[0096] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 5 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 6 As shown.
[0097] Example 4
[0098] 0.02 mmol of peptide A2 (Ac-Lys-Leu-Ala-Phe-Lys-OMe), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were sequentially added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-phenylenediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-phenylenediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, a 33-membered ring peptide, was obtained as B4. LC yield is 67%.
[0099] The reaction formula and the structural characterization data of the resulting product are shown below:
[0100]
[0101] HRMS-ESI(m / z):calcd for [MH] - C 43 H 62 N9O7S2 - :880.4219; found:880.4218.
[0102] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 7 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 8 As shown.
[0103] Example 5
[0104] 0.02 mmol of peptide A3 (acetyl tetrapeptide-3), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyl diimidazole were added to a 25 mL glass tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-phenylenediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-phenylenediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final peptide product B5, consisting of a 29-membered ring, was obtained. The LC yield was 63%.
[0105] The reaction formula and the structural characterization data of the resulting product are shown below:
[0106]
[0107] HRMS-ESI(m / z):calcd for [M+H] + C 32 H 48 N 11 O5S2 + :730.3276; found:730.3277.
[0108] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 9 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 10 As shown.
[0109] Example 6
[0110] 0.02 mmol of peptide A3 (acetyl tetrapeptide-3), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyl diimidazole were added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,8-amino-3,6-dioxooctane was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,8-amino-3,6-dioxooctane was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, B6, a 32-membered ring polypeptide, was obtained with an LC yield of 73%.
[0111] The reaction formula and the structural characterization data of the resulting product are shown below:
[0112]
[0113] HRMS-ESI(m / z):calcd for [M+H] + C 30 H 52 N 11 O7S2 + :742.3487; found:742.3491.
[0114] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 11 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 12 As shown.
[0115] Example 7
[0116] 0.02 mmol of peptide A3 (acetyl tetrapeptide-3), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 4,7,10-trioxo-1,13-tridecanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 4,7,10-trioxo-1,13-tridecanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final peptide product B7 with a 37-membered ring was obtained with an LC yield of 65%.
[0117] The reaction formula and the structural characterization data of the resulting product are shown below:
[0118]
[0119] HRMS-ESI(m / z):calcd for [M+H] + C 34 H 60 N 11 O8S2 + :814.4062; found:814.4068.
[0120] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 13 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 14 As shown.
[0121] Example 8
[0122] 0.02 mmol of peptide A3 (acetyl tetrapeptide-3), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyl diimidazole were sequentially added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, a 27-membered ring peptide B8, was obtained with an LC yield of 67%.
[0123] The reaction formula and the structural characterization data of the resulting product are shown below:
[0124]
[0125] HRMS-ESI(m / z):calcd for [M+H] + C 27 H 46 N 11 O5S2 + :668.3119; found:668.3110.
[0126] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 15 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 16 As shown.
[0127] Example 9
[0128] 0.02 mmol of peptide A4 (Val-Lys) and 0.08 mmol of N,N'-thiocarbonyldiimidazole were sequentially added to a 25 mL glass tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, a 17-membered ring peptide B9, was obtained with an LC yield of 28%.
[0129] The reaction formula and the structural characterization data of the resulting product are shown below:
[0130]
[0131] HRMS-ESI(m / z):calcd for [M+H] + C 16 H 31 N6O2S2 + :403.1944; found:403.1942.
[0132] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 17 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 18 As shown.
[0133] Example 10
[0134] 0.02 mmol of peptide A5 (a snake venom-like tripeptide), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, a 19-membered ring peptide B10, was obtained with an LC yield of 75%.
[0135] The reaction formula and the structural characterization data of the resulting product are shown below:
[0136]
[0137] HRMS-ESI(m / z):calcd for [M+H] + C 24 H 36 N7O3S2 + :534.2316; found:534.2318.
[0138] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 19 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 20 As shown.
[0139] Example 11
[0140] 0.02 mmol of peptide A6 (Ac-Lys-Ala-Ala-Trp-Ile-Lys-OMe), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were added sequentially to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, B11, a 33-membered ring polypeptide, was obtained with an LC yield of 20%.
[0141] The reaction formula and the structural characterization data of the resulting product are shown below:
[0142]
[0143] HRMS-ESI(m / z):calcd for [MH] - C 43 H 66 N 11 O8S2 - :928.4543; found:928.4536.
[0144] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 21 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 22 As shown.
[0145] Example 12
[0146] 0.02 mmol of peptide A7 (Ac-Lys-Leu-Val-Lys-OMe), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. Then, diluted 1,2-diaminocyclohexane was slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, B12, a 27-membered ring peptide, was obtained with an LC yield of 55%.
[0147] The reaction formula and the structural characterization data of the resulting product are shown below:
[0148]
[0149] HRMS-ESI(m / z):calcd for [MH] - C 31 H 55 N8O6S2 - :699.3691; found:699.3693.
[0150] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 23 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 24 As shown.
[0151] Example 13
[0152] 0.02 mmol of peptide A8 (Ac-Lys-Ala-Ala-Ile-Phe-Lys-Ala-OMe), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were sequentially added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, B13, a 33-membered ring polypeptide, was obtained with an LC yield of 70%.
[0153] The reaction formula and the structural characterization data of the resulting product are shown below:
[0154]
[0155] HRMS-ESI(m / z):calcd for [M+H] + C 44 H 72 N 11 O9S2 + :962.4950; found:962.4949.
[0156] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 25 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 26 As shown.
[0157] Example 14
[0158] 0.02 mmol of peptide A9 (anoplin), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were sequentially added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-phenylenediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through this funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, a 27-membered ring peptide B14, was obtained with an LC yield of 33%.
[0159] The reaction formula and the structural characterization data of the resulting product are shown below:
[0160]
[0161] HRMS-ESI(m / z):calcd for[(M+2H) 2+ / 2]C 65 H 116 N 18 O 10 S2 2+ / 2:668.4276; found:668.4283.
[0162] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 27 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 28 As shown.
[0163] Example 15
[0164] 0.02 mmol of peptide A9 (anoplin), 0.02 mmol of triethylamine, and 0.08 mmol of N,N'-thiocarbonyldiimidazole were sequentially added to a 25 mL glass test tube containing a magnetic stir bar. Then, 5 mL of N,N-dimethylformamide was added as a reaction solvent, and the mixture was stirred continuously at room temperature until the reaction was complete. After the reaction was complete, 0.04 mmol of 1,3-propanediamine was diluted in 20 mL of N,N-dimethylformamide and transferred to a 25 mL dropping funnel. The diluted 1,3-propanediamine was then slowly and evenly added dropwise to the aforementioned reaction tube through the funnel. After the reaction was complete, the reaction solution was lyophilized. The resulting residue was then purified by preparative HPLC, and the purified product was dried using a lyophilizer. The final product, a 27-membered ring peptide B15, was obtained with an LC yield of 30%.
[0165] The reaction formula and the structural characterization data of the resulting product are shown below:
[0166]
[0167] HRMS-ESI(m / z):calcd for[(M+2H) 2+ / 2]C 60 H 114 N 18 O 10 S2 2+ / 2:655.4198; found:655.4195.
[0168] The LC tracer diagram of the reaction solution before purification in this embodiment is as follows: Figure 29 As shown, the LC tracer chromatogram of the purified target product is as follows. Figure 30 As shown.
[0169] Example 1
[0170] In vitro antitumor experiment of a thiourea macrocyclic peptide compound:
[0171] 1. Experimental Methods:
[0172] 1.1 Cell Culture
[0173] Human colorectal adenocarcinoma (Caco-2) cells were cultured in a medium containing 10% FBS (Fetalbovine serum) and 1% Penicillin-Streptomycin antibiotics, as well as 89% RPMI Medium 1640 basic (Roswell Park Memorial Institute) medium (containing L-glutamine), at 37°C, 5% CO2, and saturated humidity. Cells in the logarithmic growth phase were used for experiments.
[0174] 1.2 CCK8 colorimetric method for detecting the effect of drugs on cell viability
[0175] (1) Collect cells in the logarithmic growth phase, centrifuge at 1000r for 3 minutes, discard the old culture medium, add an appropriate amount of fresh complete culture medium for cell counting.
[0176] (2) Adjust the cell concentration to 5x104 / mL and seed 100μl per well in a 96-well plate, which will result in 5000 cells per well.
[0177] (3) The 96-well plate was incubated at 37℃, 5% CO2 and saturated humidity for 24h.
[0178] (4) Prepare the drug into four concentrations of 256μM, 64μM, 50μM, 32μM and 16μM, and add 100μl to each well to make the concentrations in the wells 128μM, 32μM, 25μM, 16μM and 8μM respectively; add 100μl of culture medium to the control wells and blank wells.
[0179] (5) Culture the cells at 37℃, 5% CO2 and saturated humidity for 24h; after the culture is completed, add 10μl to each well.
[0180] After culturing CCK-8 (Cell Counting Kit-8) for 2-4 hours, the absorbance at 450 nm was measured using a microplate reader.
[0181] The inhibition rate of the drug can be calculated using the following formula: Inhibition rate = (OD experiment - OD blank) / OD control * 100%.
[0182] As: OD experiment: experimental group (culture medium containing cells, CCK-8, and the substance to be tested), OD blank: blank well (culture medium without cells and the substance to be tested, and CCK-8), OD control: control well (culture medium containing cells, CCK-8, and without the substance to be tested).
[0183] The in vitro antitumor experimental results of compound B15, a urea-containing macrocyclic peptide, are shown in the figure. Figure 31 , 32As shown, the compound B15 containing urea-based macrocyclic peptides of the present invention significantly enhances its inhibitory activity against Caco-2 cells (IC5). 50 =19.17μM).
[0184] Example 2
[0185] In vitro antitumor experiment of a thiourea macrocyclic peptide compound:
[0186] 1. Experimental Methods:
[0187] 1.1 Cell Culture
[0188] Human esophageal cancer cells (TE-1) were cultured in a medium containing 10% FBS (Fetalbovine serum) and 1% Penicillin-Streptomycin antibiotics, as well as 89% RPMI Medium 1640 basic (Roswell Park Memorial Institute) medium (containing L-glutamine), at 37°C, 5% CO2, and saturated humidity. Cells in the logarithmic growth phase were used for experiments.
[0189] 1.2 CCK8 colorimetric method for detecting the effect of drugs on cell viability
[0190] (1) Collect cells in the logarithmic growth phase, centrifuge at 1000r for 3 minutes, discard the old culture medium, add an appropriate amount of fresh complete culture medium for cell counting.
[0191] (2) Adjust the cell concentration to 5x104 / mL and seed 100μl per well in a 96-well plate, which will result in 5000 cells per well.
[0192] (3) The 96-well plate was incubated at 37℃, 5% CO2 and saturated humidity for 24h.
[0193] (4) Prepare the drug at four concentrations: 400 μM, 200 μM, 100 μM, 50 μM, and 13 μM, and add 100 μl of each to the experimental well.
[0194] In the experiment, the concentrations in the wells were adjusted to 200 μM, 100 μM, 50 μM, 25 μM, and 6.25 μM; 100 μl of culture medium was added to the control wells and blank wells.
[0195] (5) Culture the cells at 37℃, 5% CO2, and saturated humidity for 24 h; after the culture is complete, add 10 μl of the solution to each well.
[0196] After culturing CCK-8 (Cell Counting Kit-8) for 2-4 hours, the absorbance at 450 nm was measured using a microplate reader.
[0197] The inhibition rate of the drug can be calculated using the following formula: Inhibition rate = (OD experiment - OD blank) / OD control * 100%.
[0198] As: OD experiment: experimental group (culture medium containing cells, CCK-8, and the substance to be tested), OD blank: blank well (culture medium without cells and the substance to be tested, and CCK-8), OD control: control well (culture medium containing cells, CCK-8, and without the substance to be tested).
[0199] The in vitro antitumor experimental results of compound B15, a urea-containing macrocyclic peptide, are shown in the figure. Figure 33 , 34 As shown, its IC50 value for TE-1 cells was measured. 50 =34.33μM.
[0200] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.
Claims
1. The use of a thiourea macrocyclic peptide in the preparation of a drug for treating antitumor diseases, characterized in that, The tumor cells are Coca-Cola 2 cells and / or TE-1 cells; the structural formula of the thiourea macrocyclic peptide is shown below: 。 2. The application according to claim 1, characterized in that, The preparation method of the thiourea macrocyclic peptide includes the following steps: mixing the polypeptide, base and N,N'-thiocarbonyl diimidazole with a reaction solvent, stirring and reacting, and after the reaction is complete, slowly adding the diamine compound, diluted with solvent, dropwise to the aforementioned reaction system. After the reaction is complete, the reaction solution is freeze-dried, separated and purified to obtain the thiourea macrocyclic peptide. The polypeptide is GLLKRIKVLL-NH2; The diamine compound is 1,3-propanediamine.
3. The application according to claim 2, characterized in that, The molar ratio of the polypeptide to the N,N'-thiocarbonyldiimidazole is 1:(1~5).
4. The application according to claim 2, characterized in that, The molar ratio of the polypeptide to the diamine compound is 1:
2.
5. The application according to claim 2, characterized in that, The base is triethylamine.
6. The application according to claim 2, characterized in that, The reaction solvent is one or two of acetonitrile, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, and tetrahydrofuran.
7. The application according to claim 2, characterized in that, All reactions were carried out at room temperature, in an air atmosphere, and under non-directly exposed conditions, with a reaction time of 12-24 hours.
Citation Information
Patent Citations
Application of Anoplin in treatment of esophageal cancer
CN103142995A
Preparation method and application of thiourea functionalized multi-chiral binuclear Ir (III) metal-organic double helix structure
CN114437136A
Cyclic peptide compound as well as preparation method and application thereof
CN117820421A
